Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pirfenidone controlled-release - Overseas Pharmaceuticals

X
Drug Profile

Pirfenidone controlled-release - Overseas Pharmaceuticals

Alternative Names: Pirfenidone modified release - Overseas Pharmaceuticals

Latest Information Update: 19 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Overseas Pharmaceuticals
  • Class Anti-inflammatories; Antifibrotics; Heart failure therapies; Pyridones; Small molecules
  • Mechanism of Action Collagen inhibitors; Cytokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Idiopathic pulmonary fibrosis

Most Recent Events

  • 26 Aug 2024 Preclinical trials in Idiopathic pulmonary fibrosis in China (PO), prior to August 2024
  • 23 Aug 2024 Overseas Pharmaceuticals plans a phase I trial for Idiopathic pulmonary fibrosis (In volunteers) in China (PO, Tablet), in August 2024 (NCT06569381)
  • 27 Apr 2024 Overseas Pharmaceuticals completes a phase I trial in Idiopathic pulmonary fibrosis (In volunteers) in China (PO) (NCT06588517)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top